PLS3 Mutations in X-Linked Osteoporosis: Clinical and Genetic Features in Five New Families

Calcif Tissue Int. 2024 Feb;114(2):157-170. doi: 10.1007/s00223-023-01162-4. Epub 2023 Dec 3.

Abstract

Childhood-onset osteoporosis is a rare but clinically significant condition. Studies have shown pathogenic variants in more than 20 different genes as causative for childhood-onset primary osteoporosis. The X-chromosomal PLS3, encoding Plastin-3, is one of the more recently identified genes. In this study, we describe five new families from four different European countries with PLS3-related skeletal fragility. The index cases were all hemizygous males presenting with long bone and vertebral body compression fractures. All patients had low lumbar spine bone mineral density (BMD). The age at the first clinical fracture ranged from 1.5 to 13 years old. Three of the identified PLS3 variants were stop-gain variants and two were deletions involving either a part or all exons of the gene. In four families the variant was inherited from the mother. All heterozygous women reported here had normal BMD and no bone fractures. Four patients received bisphosphonate treatment with good results, showing a lumbar spine BMD increment and vertebral body reshaping after 10 months to 2 years of treatment. Our findings expand the genetic spectrum of PLS3-related osteoporosis. Our report also shows that early treatment with bisphosphonates may influence the disease course and reduce the progression of osteoporosis, highlighting the importance of early diagnosis for prompt intervention and appropriate genetic counseling.

Keywords: Early-onset osteoporosis; Fragility fractures; Osteoporosis in children; PLS3.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Bone Density / genetics
  • Child
  • Child, Preschool
  • Diphosphonates / therapeutic use
  • Female
  • Fractures, Bone* / drug therapy
  • Humans
  • Infant
  • Lumbar Vertebrae / pathology
  • Male
  • Mutation
  • Osteoporosis* / drug therapy
  • Spinal Fractures* / drug therapy
  • Spinal Fractures* / genetics

Substances

  • Diphosphonates
  • plastin